Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
Wei‐Feng Qu(Ministry of Education of the People's Republic of China), Ying–Hong Shi(Ministry of Education of the People's Republic of China), Zi‐Han Zhang(Fudan University), Wei‐Ren Liu(Chung Yuan Christian University), Xiutao Fu(Fudan University), Xiaoling Wu(Fudan University), Chenyang Tao(Ministry of Education of the People's Republic of China), Jun Gao(Nanchang University), Xin Zhang(Fudan University), Jia Fan(Nanjing Tech University), Min Tang(Central South University), Jian Zhou(Ministry of Education of the People's Republic of China), Zheng Tang(Ministry of Education of the People's Republic of China), Run Huang(Ministry of Education of the People's Republic of China), Yuan Fang(Guangzhou University of Chinese Medicine), Meng‐Xin Tian(Sun Yat-sen University), Ao Huang(Beijing University of Civil Engineering and Architecture), Guiqi Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xu-Dong Qu(Fudan University), Xi‐Fei Jiang(Sun Yat-sen University), Zhen‐Bin Ding(Fudan University)
Cited by 58
Related Papers
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
|Liver Cancer|2020|828